THE IMPACT OF IL-6 AND TNF INHIBITORS ON HEMOGLOBIN LEVELS: AN ANALYSIS FROM RHUMADATA® CLINICAL DATABASE AND REGISTRY

Denis Choquette1, Louis Bessette1, Lolic Choquette Sauvageau1, Isabelle Ferdinand1, Paul Pelletier1, Jean-Pierre Raynauld1, Marie-Anna Rémillard1, Diane Sauvageau1, Edith Villeneuve1, Louis Coupal1, Institut de Recherche en Rhumatologie de Montréal (IRRMM), Rhumatology, Montréal, Canada; Centre de l’Ostéoporose et de Rhumatologie de Québec (CORQ), Rhumatology, Québec, Canada

Background: Anemia is a common feature of RA. Prior to the appearance of biologic treatments, improvement of hemoglobin (Hb) levels was unusual and inconsistent. With better control of the inflammatory process by cytokine inhibitors, it has been shown that Hb levels can improve substantially. The impact of the development of IL-6 receptor antagonists (siltuximab (SARI) and tocilizumab (TOCI)) data have shown improvement in Hb levels related to the down-regulation of hepcidin. No direct comparison of Hb levels between TNF and IL-6 inhibition has been explored in observational data (1).

Objectives: This analysis compares the impact of TNF and IL-6 inhibitors on Hb levels.

Methods: Data collected since January 1, 2015 (when TOCI and SARI were available in Canada) at the Institut de Recherche en Rhumatologie de Montréal (IRRMM) and the Centre de l’Ostéoporose et de Rhumatologie de Québec (CORQ) was extracted from the Rhumadata® clinical database and registry on January 7, 2019. Selected patients were those initiated on an IL-6 antagonist or a TNF (adalimumab, certolizumab, etanercept, golimumab or infliximab) and had been treated for at least one year. Furthermore, patients were cancer free and had no diagnosis of Crohn’s disease or ulcerative colitis and had creatinine (Cr) and ALT levels within the normal sex-specific range. IL-6 patients were matched (ratio 1:2) to TNFi patients based on age at treatment initiation, gender and baseline Hb. The collected data include baseline characteristics (socio-demographic variables, concomitant and past medication, comorbidities and the Charlson comorbidity index (CCI)), variables measured over time (Hb and other laboratory test results, patient and physician-reported outcomes, and disease activity measures such as CDAI and DAS28(4)-ESR). The groups were compared to identify potential confounder.

Results: A total of 145 patients initiating an IL-6 inhibitor since January 1, 2015 were matched with 286 patients prescribed a TNF inhibitor during the same time-period. Most patients were women (86%), the mean age at treatment initiation was 54.1 (standard deviation=11.7) years, and 16% were smokers. Baseline patient global, pain and fatigue assessments, made on a visual analogue scale ranging from 1 to 10, were 5.4 (2.5), 5.1 (2.5) and 5.5 (3.0) in the IL6 group and 5.1 (2.7), 5.5 (3.0) and 5.0 (3.2) in the TNFi group. Baseline disease activity was assessed as moderate or high/severe in 85.5% (IL6) and 85.9% (TNFi) of patients (DAS28(4)-ESR criteria). At treatment initiation, mean Hb level was 126.6 (12.4) g/L and Cr and ALT levels were 66.2 (11.5) umol/L and 18.7 (6.5) U/L in the IL6 group and 67.0 (12.0) umol/L and 19.3 (6.8) U/L in the TNFi group.

Conclusion: This analysis confirms that IL-6 inhibition provides a numerically and statistically superior increase in Hb over TNFi.

REFERENCE:

DISCLOSURE OF INTERESTS: Denis Choquette Grant/research support from: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Louis Bessette Grant/research support from: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Lolic Choquette Sauvageau: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Speakers bureau: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Jean-Pierre Raynauld Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Marie-Anna Rémillard Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Diane Sauvageau Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Edith Villeneuve Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz, Louis Coupal Consultant for: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Sandoz.

TAPERING OF BIOLOGICAL ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS: ACHIEVABLE AND COST EFFECTIVE IN DAILY CLINICAL PRACTICE: DATA FROM THE BRUSSELS UCL RA COHORT

Stéphanie Dierckx1, Bernard Lauwerys2, Tatiana Sokolova2, Laurent Mercier de Bellefon3, Maria Stoenu2, Adrien Nzeusu2, Frederic Housiaux2, Aleksandra Avramovska2, Patrick Durez2, Rheumatology department, CHU UCL Namur, Yvoir, Belgium; 2Rheumatology department, Cliniques universitaires Saint-Luc – Université catholique de Louvain – Institut de Recherche Experimentale et Clinique (IREC), Brussels, Belgium

Background: Several studies have demonstrated that Rheumatoid Arthritis (RA) patients achieving low disease activity or remission are able to taper biological disease-modifying antirheumatic drugs (bDMARDs). The aim of this study is to evaluate the proportion of patients in whom the bDMARD can be tapered in daily practice and to analyse the characteristics of these patients. Another objective is to determine which bDMARDs are more adapted to dose reduction and the cost saving.

Methods: Inclusion criteria were RA patients from our Brussels UCL cohort treated with a bDMARD for at least one year. A dose reduction was proposed by the senior physician when sustained low disease activity or remission was achieved. Patient characteristics and baseline features before the introduction of the current bDMARD were collected as well as flares if happened. We also calculated, for each bDMARD, the proportion of patients who received a decreased dose and the annual cost.

Results: Data from 332 eligible RA patients were collected, 140 patients (42.1%) had a tapered regime and 192 received a full dose of bDMARD. In the decreased dose group, age at diagnosis (43.1 vs 38.7 years, p=0.004), HAQ (1.3 vs 1.5, p=0.048), RF (83.3 vs 72.9%, p=0.016) and disease duration at the bDMARDs introduction (9.7 vs 12.1 years, p=0.034) were statistically different. As expected, the current DAS28-CRP was lower (2.26 vs 2.64, p=0.001) in the decreased dose group and interestingly, more patients receiving a decreased dose were treated with a combination of methotrexate when the bDMARD was introduced (86.7% vs 73.8%, p=0.005). No difference between groups was observed for gender, ACPA, erosion, number of previous bDMARDs, time to first conventional synthetic DMARD and biological DMARD, baseline DAS28-CRP and use of glucocorticoids. In our cohort, anti-TNF agents were the most commonly prescribed medications (anti-TNF 68%, tocilizumab 15%, rituximab 10%, abatacept 7%). Only 15 patients experienced a flare during the follow-up. Adalimumab, etanercept and rituximab were the most frequently decreased bDMARD and were associated with the most important reduction of annual cost.

Conclusion: In daily practice, tapering of bDMARDs in RA patients with low disease activity or remission is an achievable goal in a large proportion of patients, thereby reducing annual drug cost. The combination with methotrexate could be a positive predictive factor for the success of bDMARD tapering, but further prospective research in daily practice is needed to confirm this result.

DISCLOSURE OF INTERESTS: Stéphanie Dierckx: None declared, Bernard Lauwerys: None declared, Tatiana Sokolova: None declared, Laurent Mercier de Bellefon: None declared, Maria Stoenu: Research Grant/support from: Abbvie, Roche, Wyeth, Adrien Nzeusu: None declared, Frederic Housiaux: None declared, Aleksandra Avramovska: None declared, Patrick Durez: Speakers bureau: Bristol-Myers Squibb, Eli Lilly, Sanofi, Celltrion.


Figure 1. Proportion of patients with decreased dose for each bDMARD


Conclusion: In daily practice, tapering of bDMARDs in RA patients with low disease activity or remission is an achievable goal in a large proportion of patients, thereby reducing annual drug cost. The combination with methotrexate could be a positive predictive factor for the success of bDMARD tapering, but further prospective research in daily practice is needed to confirm this result.

Disclosure of Interests: Stephanie Dierckx: None declared, Bernard Lauwerys: None declared, Tatiana Sokolova: None declared, Laurent Mercier de Bellefon: None declared, Maria Stoenu: Grant/research support from: Abbvie, Roche, Wyeth, Adrien Nzeusu: None declared, Frederic Housiaux: None declared, Aleksandra Avramovska: None declared, Patrick Durez: Speakers bureau: Bristol-Myers Squibb, Eli Lilly, Sanofi, Celltrion.
